260 related articles for article (PubMed ID: 32930994)
1. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).
Ford J; Tassorelli C; Leroux E; Wang S; Ayer D; Nichols R; Detke H
Qual Life Res; 2021 Jan; 30(1):105-115. PubMed ID: 32930994
[TBL] [Abstract][Full Text] [Related]
2. Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study.
Ford JH; Stauffer VL; McAllister P; Akkala S; Sexson M; Ayer DW; Wang S
Qual Life Res; 2021 Feb; 30(2):455-464. PubMed ID: 32944843
[TBL] [Abstract][Full Text] [Related]
3. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).
Tepper SJ; Ailani J; Ford JH; Nichols RM; Li LQ; Kemmer P; Hand AL; Tockhorn-Heidenreich A
Clin Drug Investig; 2022 Mar; 42(3):263-275. PubMed ID: 35041159
[TBL] [Abstract][Full Text] [Related]
4. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
5. Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Ford JH; Kurth T; Starling AJ; Ayer DW; Wietecha LA; Port MD; Rettiganti M; Ruff DD
Headache; 2020 Nov; 60(10):2304-2319. PubMed ID: 33249580
[TBL] [Abstract][Full Text] [Related]
6. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
7. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability.
Ford JH; Ayer DW; Zhang Q; Carter JN; Leroux E; Skljarevski V; Aurora SK; Tockhorn-Heidenreich A; Lipton RB
Neurology; 2019 Jul; 93(5):e508-e517. PubMed ID: 31270220
[TBL] [Abstract][Full Text] [Related]
8. Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).
Tobin JA; Joshi S; Ford JH; Nichols RM; Foster SA; Ruff D; Detke HC; Aurora SK
J Med Econ; 2022; 25(1):1030-1038. PubMed ID: 35971655
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
[TBL] [Abstract][Full Text] [Related]
10. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
Pozo-Rosich P; Detke HC; Wang S; Doležil D; Li LQ; Aurora SK; Reuter U
Curr Med Res Opin; 2022 May; 38(5):731-742. PubMed ID: 35392739
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
15. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
[TBL] [Abstract][Full Text] [Related]
16. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
Reuter U; Lucas C; Dolezil D; Hand AL; Port MD; Nichols RM; Stroud C; Tockhorn-Heidenreich A; Detke HC
Adv Ther; 2021 Nov; 38(11):5465-5483. PubMed ID: 34542830
[TBL] [Abstract][Full Text] [Related]
17. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
19. Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Varnado OJ; Ye W; Mi X; Burge R; Hall J
J Med Econ; 2023; 26(1):149-157. PubMed ID: 36601798
[TBL] [Abstract][Full Text] [Related]
20. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]